Diabetic Retinopathy

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

Researchers from the Czech Republic found that an AI system showed higher sensitivity and specificity for screening diabetic retinopathy compared to telemedicine evaluations.

Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary antibody biopolymer conjugate (ABC) platform.

A recent study of AEYE-DS AI technology used in conjunction with the Topcon NW500 resulted in exceptional clinical diagnostic efficacy.

DRSS stable/improved with OKT-TKI; drug well tolerated

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding that you may have missed.

Roche, Ainnova, and Salud 360 signed this alliance to improve access to vision screening in patients with uncontrolled diabetes.

A case report demonstrates independent effect of GLP-1 receptor agonist.

A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need for improved awareness, cost-effectiveness, and integration to increase diabetic retinopathy screening rates.

Christina Y. Weng, MD, MBA, shared insights from recent publications on teleretinal screenings for diabetic retinopathy. She will be presenting an overview of these findings at the annual American Academy of Ophthalmology meeting being held in Chicago, Illinois during a talk entitled, "The use of teleretinal screening for diabetic retinopathy."

In the first five months of the program at Henrietta Johnson Medical Center, 26% of patients with images gradable by EyeArt tested positive for either more-than-mild or vision-threatening diabetic retinopathy.

AEYE Health will attend the American Academy of Ophthalmology (AAO) Annual Meeting, from October 18-21 in Chicago.

Shruti Sharma, PhD, and a team from the MCG Center for Biotechnology and Genomic Medicine, hope to focus in on a new treatment pathway for diabetic retinopathy.

Dilsher Dhoot, MD, sat down with Modern Retina to provide some insights on the phase 1 HELIOS trial, which he presented on during the 2024 ASRS meeting held in Stockholm, Sweden earlier in 2024.

Dvey-Aharon is an internationally known AI expert and the inventor of AEYE-DS.

Efferocytosis’ role in retinopathy is largely unknown despite knowledge of the process in other diseases.

Michael Abramoff, MD, PhD, a retina specialist and founder and executive chairman of Digital Diagnostics, points out that much evidence has been collected over the past few decades showing that early detection is key.

In a study, a team of researchers with the OhioHealth Grant Medical Center Family Medicine practice implemented diabetic retinopathy screening using in-clinic retinal photographs and automated software analysis to increase screening rates.

The 2-year Phase III data presented at the American Society of Retina Specialists 2024 in Stockholm, Sweden, show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

Paolo Antonio Silva, MD, discusses his presentation on diabetic retinopathy lesion types and distribution on ultra-widefield imaging and the risk for disease worsening over time at the American Society of Retina Specialists meeting held in Stockholm, Sweden.